Bris­tol-My­ers dou­bles down on PsiOxus in $936M-plus “armed” on­colyt­ic virus deal

Bris­tol-My­ers Squibb $BMY is tak­ing its re­la­tion­ship with PsiOxus to the prover­bial next lev­el. The big biotech is grab­bing rights to the Ox­ford-based com­pa­ny’s next-gen on­colyt­ic virus ther­a­py, which em­ploys a trio of tu­mor cell-killing ap­proach­es to rein in can­cer.

Al­ready al­lied on a com­bi­na­tion of Op­di­vo with PsiOxus’ lead­ing on­colyt­ic virus, enade­no­tu­cirev, Bris­tol-My­ers has come back for NG-348, an “armed” on­colyt­ic virus that adds im­muno-ther­a­peu­tic trans­genes to the can­cer cell de­stroy­ing mix. Bris­tol-My­ers is of­fer­ing $50 mil­lion up­front, along with new re­search sup­port and up to $886 mil­lion in mile­stones if all the cards turn in its fa­vor.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN